Medivation

Here's a quick look at nine of the best-performing biotech stocks of the past year. Achillion Pharmaceuticals (NASDAQ: ACHN) is up almost 88% year to date and about 37% higher just in the past month. This Connecticut-based biopharmaceutical company has three drugs in clinical trials to treat...

San Francisco-based Medivation (NASDAQ: MDVN) has made a breakthrough in the fight against breast cancer while researching a drug initially intended for use by patients with prostate cancer. According to a statement sent to Benzinga by account manager Joey Fleury of BioPharma, results from a...

J.P. Morgan is out with its report today on Medivation (NASDAQ: MDVN), maintaining Neutral. In a note to clients, J.P. Morgan writes, "Our December 2011 price target of $12 is based on our probability-adjusted NPV analysis of MDV3100 and net cash. We assume a 20% probability of success for MDV...

Brean Murray, Carret & Co. is reiterating its Sell rating on shares of Medivation, Inc. (NASDAQ: MDVN). “Medivation reported revenue of $16.6 million and EPS of ($0.11), neither of which is all that meaningful at Medivation's present stage,” Brean Murray, Carret & Co. writes. “The revenue...

Medivation, Inc. (NASDAQ: MDVN) expects to release top-line data from the Phase 3 HORIZON trial, evaluating dimebon's potential benefits in 403 patients with Huntington disease, in 1H11, Hapoalim Securities reports. “Based on dimebon's lack of efficacy in Alzheimer's, we remain skeptical that the...

Leerink Swann analysts Howard Liang and Jonathan Eckard rated shares of Medivation, Inc. (Nasdaq: MDVN) a Market Perform with a valuation of $14. The analysts said that the negative readout for the Phase III CONNECTION trial for Dimebon, without any efficacy signal, leads them to believe that...

Roth Capital upgraded Medivation (NASDAQ: MDVN) from “hold” to “buy.” The upgrade was based on a 65% probability of the FDA approving Medivation's Alzheimer treatment, Dimebon. Roth Capital has set the target price for MDVN at $34 and has recommended purchase of MDVN shares before the company...